FTY720

DRUG16 trials

Sponsors

Novartis Pharmaceuticals, Novartis

Conditions

Acute Noninfectious Posterior, Intermediate, or Pan UveitisAsthmaHealthyKidney TransplantationMultiple SclerosisPrimary Progressive Multiple SclerosisRelapsing Multiple SclerosisRenal Transplantation

Phase 1

Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers

CompletedNCT00416845

NovartisHealthy

Start: 2006-10-31Updated: 2010-06-04

Phase 2

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

CompletedNCT00239902

Novartis PharmaceuticalsRenal Transplantation

Start: 2002-05-31Target: 396Updated: 2011-11-02

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

CompletedNCT00239798

Novartis PharmaceuticalsRenal Transplantation

Start: 2004-11-30Target: 255Updated: 2017-02-23

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis

CompletedNCT00333138

NovartisMultiple Sclerosis

Start: 2003-05-31End: 2011-04-30Updated: 2017-09-15

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

CompletedNCT00537082

NovartisMultiple Sclerosis

Start: 2007-09-30Updated: 2011-04-21

A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma

CompletedNCT00785083

Start: 2008-09-30Updated: 2016-11-18

Study of FTY720 in Patients With Uveitis

WithdrawnNCT01791192

Novartis PharmaceuticalsAcute Noninfectious Posterior, Intermediate, or Pan Uveitis

Start: 2013-11-30End: 2014-10-31Updated: 2017-04-20

Phase 3

Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation

CompletedNCT00098735

Novartis PharmaceuticalsKidney Transplantation

Start: 2004-04-30Target: 140Updated: 2016-11-18

Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

CompletedNCT00099801

Novartis PharmaceuticalsKidney Transplantation

Start: 2005-01-31End: 2006-03-31Updated: 2017-06-07

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

CompletedNCT00239876

Novartis PharmaceuticalsRenal Transplantation

Start: 2005-05-31Target: 140Updated: 2011-11-02

Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

CompletedNCT00239811

Novartis PharmaceuticalsRenal Transplantation

Start: 2004-04-30Target: 684Updated: 2011-11-02

Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients

CompletedNCT00239863

Novartis PharmaceuticalsRenal Transplantation

Start: 2004-05-31Target: 684Updated: 2017-02-23

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

CompletedNCT00239785

Novartis PharmaceuticalsRenal Transplantation

Start: 2003-04-30Target: 684Updated: 2017-08-22

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

TerminatedNCT00731692

Novartis PharmaceuticalsPrimary Progressive Multiple Sclerosis

Start: 2008-07-28End: 2015-06-22Updated: 2017-06-14

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

CompletedNCT01127750

NovartisRelapsing Multiple Sclerosis

Start: 2010-05-31End: 2011-10-31Updated: 2017-02-23

Phase 4

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

CompletedNCT01585298

Novartis PharmaceuticalsMultiple Sclerosis

Start: 2012-04-29End: 2016-12-12Updated: 2019-09-23

Related Papers

Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials

Neurology2025-04-214 citations

Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis.

2023-10-129 citations

Blood Neurofilament Light in Progressive Multiple Sclerosis

Neurology2022-04-0447 citations

Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset.

2021-08-156 citations

Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.

2021-08-1025 citations

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis

Multiple Sclerosis Journal - Experimental Translational and Clinical2020-01-016 citations

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

2018-01-3022 citations

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis

Frontiers in Neuroscience2017-10-1215 citations

Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study.

2017-01-2813 citations

Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.

2017-01-1817 citations

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

2016-01-28336 citations

Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.

2014-01-2939 citations

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

2006-09-01761 citations